CY1105657T1 - Θεραπεια ηπατιτιδας c με θυμοσινη και σταθεροποιημενη ιντερφερονη - Google Patents

Θεραπεια ηπατιτιδας c με θυμοσινη και σταθεροποιημενη ιντερφερονη

Info

Publication number
CY1105657T1
CY1105657T1 CY20061101460T CY061101460T CY1105657T1 CY 1105657 T1 CY1105657 T1 CY 1105657T1 CY 20061101460 T CY20061101460 T CY 20061101460T CY 061101460 T CY061101460 T CY 061101460T CY 1105657 T1 CY1105657 T1 CY 1105657T1
Authority
CY
Cyprus
Prior art keywords
hepatitis
thymosin
treatment
stabilized interferon
effective amount
Prior art date
Application number
CY20061101460T
Other languages
English (en)
Inventor
Alfred R. Rudolph
Original Assignee
Sciclone Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals, Inc. filed Critical Sciclone Pharmaceuticals, Inc.
Publication of CY1105657T1 publication Critical patent/CY1105657T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μια μέθοδος και ένας φαρμακευτικός συνδυασμός για τη θεραπεία ηπατίτιδας C με τη χορήγηση σε έναν ασθενή που πάσχει από ηπατίτιδα C μιας δραστικής ποσότητας τουλάχιστον μιας θυμοσίνης ή μιας δραστικής ποσότητας τουλάχιστον ενός τμήματος θυμοσίνης, σε συνδυασμό με τη χορήγηση στον ασθενή με ηπατίτιδα C μιας δραστικής ποσότητας τουλάχιστον μιας σταθεροποιημένης ιντερφερόνης.
CY20061101460T 2000-08-07 2006-10-12 Θεραπεια ηπατιτιδας c με θυμοσινη και σταθεροποιημενη ιντερφερονη CY1105657T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22331200P 2000-08-07 2000-08-07
PCT/US2001/041549 WO2002011754A1 (en) 2000-08-07 2001-08-06 Treatment of hepatitis c with thymosin and pegylated interferon

Publications (1)

Publication Number Publication Date
CY1105657T1 true CY1105657T1 (el) 2010-12-22

Family

ID=22835968

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101460T CY1105657T1 (el) 2000-08-07 2006-10-12 Θεραπεια ηπατιτιδας c με θυμοσινη και σταθεροποιημενη ιντερφερονη

Country Status (12)

Country Link
EP (1) EP1311286B1 (el)
CN (1) CN1461221A (el)
AT (1) ATE332704T1 (el)
AU (2) AU8716001A (el)
CA (1) CA2418154A1 (el)
CY (1) CY1105657T1 (el)
DE (1) DE60121449T2 (el)
DK (1) DK1311286T3 (el)
ES (1) ES2267810T3 (el)
HK (1) HK1056117A1 (el)
PT (1) PT1311286E (el)
WO (1) WO2002011754A1 (el)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy

Also Published As

Publication number Publication date
DE60121449T2 (de) 2007-02-01
EP1311286A1 (en) 2003-05-21
PT1311286E (pt) 2006-11-30
CA2418154A1 (en) 2002-02-14
HK1056117A1 (en) 2004-02-06
EP1311286A4 (en) 2004-01-28
CN1461221A (zh) 2003-12-10
DK1311286T3 (da) 2006-10-30
EP1311286B1 (en) 2006-07-12
DE60121449D1 (de) 2006-08-24
ES2267810T3 (es) 2007-03-16
ATE332704T1 (de) 2006-08-15
AU2001287160B2 (en) 2005-08-18
AU8716001A (en) 2002-02-18
WO2002011754A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
CY1107615T1 (el) Θεραπευτικοι συνδυασμοι αντιυπερτασικων και αντιαγγειογενετικων παραγοντων
CY1118429T1 (el) Αντισωμα συνδεσης αλφα4βητα7 ιντεγκρινης και η χρηση αυτου εις τη θεραπευτικη αγωγη της φλεγμονωδους νοσου του εντερου
CY1108765T1 (el) ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2
CY1107314T1 (el) Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη
CY1110894T1 (el) Μεθοδοι για θεραπεια ή προληψη αγγειακης φλεγμονης χρησιμοποιωντας αναστολεα (-εις) απορροφησης στερολης
DE60215787D1 (de) Behandlung von typ ii diabetes mit dipeptidyl-peptidase-iv-hemmern
UY26724A1 (es) Métodos y composiciones para tratar el virus de la hepatitis c
DK1169059T3 (da) Docetaxel i kombination med rhuMAb HER2 til behandling af cancere
CY1105768T1 (el) L-fmau για την αντιμετωπιση μολυνσης απο ιο της ηπατιτιδας δελτα
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
CY1105657T1 (el) Θεραπεια ηπατιτιδας c με θυμοσινη και σταθεροποιημενη ιντερφερονη
FI954127A (fi) Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa
FR2839450B1 (fr) Preparation medicamenteuse notamment pour le traitement des hernies discales
WO2003068156A3 (en) Methods for treating or inhibiting sick building syndrome, post-lyme disease syndrome, and/or chronic fatigue syndrome
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
TR199801801T2 (xx) Madde k�t�ye kullan�m�n�n tedavisi.
EA199800822A1 (ru) Способ лечения избыточной агрессии
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
EA199800820A1 (ru) Способ лечения злоупотребления лекарственными средствами
CY1117275T1 (el) Μεθοδοι θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος enanti-erbb-μεϊτανσινοειδους
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica